Loading company…
Vibrant Therapeutics develops AI-enabled research tools and macromolecular drug candidates, primarily for immuno-oncology.
Founded in 2019, Xinhua Biopharmaceuticals (Guangzhou) Co., Ltd., trading as Vibrant Therapeutics, develops macromolecular drugs using artificial intelligence. Based in Cambridge, US, it has an AI-driven platform for target identification, molecular design and efficacy evaluation, and launched the VibrantFold antibody structure prediction tool. Its candidates focus on immuno-oncology, particularly solid tumors. In January 2026, it raised USD 61 million from Apricot Capital, Pfizer Venture Investments, Bayland Capital, HSG, NLVC. and First Principal Venture Limited.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in